Guggenheim analyst Subbu Nambi yesterday morning initiated coverage of Twist Bioscience with a Buy rating and $53 price target. The company has a unique DNA synthesis platform that enables a wide range of products with applications in synthetic biology, next-generation sequencing, and even drug discovery, the analyst tells investors in a research note. The firm says Twist’s “considerable growth” in the next-generation sequencing, market appears poised to expand in the coming years. It finds the stock’s risk/reward as “quite compelling.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $48 from $43 at Scotiabank
- Evercore ISI removes several healthcare names from ‘Tactical Outperform’ list
- Twist Bioscience price target raised to $28 from $25 at JPMorgan
- Twist Bioscience price target raised to $55 from $48 at TD Cowen
- Twist Bioscience price target raised to $40 from $39 at Baird